Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Monitoring of telomere dynamics in peripheral blood leukocytes in relation to colorectal cancer patients' outcomes

K. Tomasova, M. Kroupa, A. Zinkova, M. Korabecna, V. Vymetalkova, P. Skrobanek, L. Sojka, M. Levy, K. Hemminki, V. Liska, P. Hosek, R. Kumar, L. Vodickova, P. Vodicka

. 2022 ; 12 (-) : 962929. [pub] 20220920

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031707

We investigated the possible associations between leukocyte telomere length, therapy outcomes, and clinicopathological features in patients with colorectal cancer. Additionally, telomerase reverse transcriptase (TERT) expression was evaluated. Telomere length was measured using singleplex qPCR in 478 consecutive leukocyte DNA samples from 198 patients. Blood was drawn at diagnosis prior to any therapy and then at 6-month intervals for 18 months. Following diagnosis, the telomeres gradually shortened during the course of the treatment regardless of the patient's age. The most pronounced decrease was observed 12 months after the diagnosis (p < 0.0001). Based on tumor localization, the decrease in telomere length one year after the diagnosis followed different trajectories (p = 0.03). In patients treated with adjuvant therapy, telomere length correlated with the time elapsed after completion of therapy (p = 0.03). TERT expression did not correlate with the telomere length; however, it was higher in women than men (1.35-fold, 95% CI 1.11-1.65, p = 0.003) and in smokers than non-smokers (1.27-fold, 95% CI 1.01-1.61, p = 0.04). Leukocyte telomere length declines naturally during aging, but the accelerated shortening observed in our patients was age-independent. Telomere length manifestly reflected chemotherapy impact and could be linked to therapy toxicity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031707
003      
CZ-PrNML
005      
20230222122331.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.962929 $2 doi
035    __
$a (PubMed)36203452
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tomasova, Kristyna $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
245    10
$a Monitoring of telomere dynamics in peripheral blood leukocytes in relation to colorectal cancer patients' outcomes / $c K. Tomasova, M. Kroupa, A. Zinkova, M. Korabecna, V. Vymetalkova, P. Skrobanek, L. Sojka, M. Levy, K. Hemminki, V. Liska, P. Hosek, R. Kumar, L. Vodickova, P. Vodicka
520    9_
$a We investigated the possible associations between leukocyte telomere length, therapy outcomes, and clinicopathological features in patients with colorectal cancer. Additionally, telomerase reverse transcriptase (TERT) expression was evaluated. Telomere length was measured using singleplex qPCR in 478 consecutive leukocyte DNA samples from 198 patients. Blood was drawn at diagnosis prior $a We investigated the possible associations between leukocyte telomere length therapy outcomes and clinicopathological features in patients with colorectal cancer Additionally telomerase reverse transcriptase TERT expression was evaluated Telomere length was measured using singleplex qPCR in 478 consecutive leukocyte DNA samples from 198 patients Blood was drawn at diagnosis prior to any t $a We investigated the possible associations between leukocyte telomere length, therapy outcomes, and clinicopathological features in patients with colorectal cancer. Additionally, telomerase reverse transcriptase (TERT) expression was evaluated. Telomere length was measured using singleplex qPCR in 478 consecutive leukocyte DNA samples from 198 patients. Blood was drawn at diagnosis prior to any therapy and then at 6-month intervals for 18 months. Following diagnosis, the telomeres gradually shortened during the course of the treatment regardless of the patient's age. The most pronounced decrease was observed 12 months after the diagnosis (p < 0.0001). Based on tumor localization, the decrease in telomere length one year after the diagnosis followed different trajectories (p = 0.03). In patients treated with adjuvant therapy, telomere length correlated with the time elapsed after completion of therapy (p = 0.03). TERT expression did not correlate with the telomere length; however, it was higher in women than men (1.35-fold, 95% CI 1.11-1.65, p = 0.003) and in smokers than non-smokers (1.27-fold, 95% CI 1.01-1.61, p = 0.04). Leukocyte telomere length declines naturally during aging, but the accelerated shortening observed in our patients was age-independent. Telomere length manifestly reflected chemotherapy impact and could be linked to therapy toxicity.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kroupa, Michal $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Zinkova, Alzbeta $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Korabecna, Marie $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Vymetalkova, Veronika $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Skrobanek, Pavel $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czechia
700    1_
$a Sojka, Ladislav $u Department of Surgery, First Faculty of Medicine, Charles Univesity and Thomayer Hospital, Prague, Czechia $7 xx0282382
700    1_
$a Levy, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles Univesity and Thomayer Hospital, Prague, Czechia
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Department of Surgery, Medical Faculty in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Hosek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Kumar, Rajiv $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u German Cancer Research Center, Heidelberg, Germany
700    1_
$a Vodickova, Ludmila $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Vodicka, Pavel $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 962929
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36203452 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230222122326 $b ABA008
999    __
$a ok $b bmc $g 1889609 $s 1183040
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 12 $c - $d 962929 $e 20220920 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace